Metallomics study in CSF for putative biomarkers to predict cerebral vasospasm

Yaofang Zhang1, Joseph F Clark, Gail Pyne-Geithman

  • 1Department of Chemistry, University of Cincinnati, OH 45221-0172, USA.

Insights

Cerebral vasospasm (CV) following subarachnoid hemorrhage (SAH) is poorly understood. Analyzing cerebrospinal fluid (CSF) identified potential protein biomarkers for predicting CV, offering hope for better patient outcomes.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Analytical Chemistry

Background:

  • Cerebral vasospasm (CV) is a dangerous narrowing of brain arteries after subarachnoid hemorrhage (SAH), often leading to poor patient outcomes.
  • A 3-7 day window exists between SAH and CV, offering a critical period for prediction and prevention.
  • Current methods for predicting CV are inefficient, highlighting the need for improved diagnostic approaches.

Purpose of the Study:

  • To investigate cerebrospinal fluid (CSF) components as potential indicators of SAH and the development of CV.
  • To identify novel biomarkers in CSF for predicting and potentially preventing CV after SAH.

Main Methods:

  • Analysis of CSF from healthy controls, SAH patients, and SAH patients with CV.
  • Utilized two-dimensional separations coupled with elemental and molecular mass spectrometry.
  • Employed size exclusion chromatography (SEC) with ICP-MS for metal species analysis.
  • Applied RP-Chip/electrospray MS and database searching for metallopeptide and metalloprotein identification.

Main Results:

  • Distinct molecular distribution patterns of metal species (Fe, Ni, Cu, Zn, Pb) were observed in CSF across the three groups.
  • Identified potential metallopeptides and metalloproteins in tryptic digests of CSF.
  • Discovered six protein families that may serve as candidate biomarkers for CV prediction.

Conclusions:

  • Alterations in CSF components, particularly specific proteins and metal-binding species, correlate with SAH and CV.
  • These identified protein families represent promising targets for developing effective biomarkers to predict and prevent CV.
  • Further research into these CSF biomarkers could significantly improve management of SAH patients.